# An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications

> **NCT02082249** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 30 (actual)

## Conditions studied

- Advanced Parkinson's Disease

## Interventions

- **DRUG:** ABT-SLV187

## Key facts

- **NCT ID:** NCT02082249
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-10
- **Primary completion:** 2019-10-31
- **Final completion:** 2019-10-31
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02082249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02082249, "An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02082249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*